Compare · TXG vs WAT
TXG vs WAT
Side-by-side comparison of 10x Genomics Inc. (TXG) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TXG and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $35.67B, about 9.6x TXG ($3.70B).
- TXG has been more active in the news (10 items in the past 4 weeks vs 8 for WAT).
- Both have 25 recent analyst ratings on file.
- Company
- 10x Genomics Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- $3.70B
- $35.67B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- 1995
- News (4w)
- 10
- 8
- Recent ratings
- 25
- 25
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest TXG
- Director Teichmann Sarah A. was granted 8,829 shares, increasing direct ownership by 33% to 35,609 units (SEC Form 4)
- Director Suliman Shehnaaz was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)
- Director Stuelpnagel John R was granted 8,829 shares, increasing direct ownership by 2% to 368,436 units (SEC Form 4)
- Director Popovits Kimberly J was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)
- Director Mateo Alan was granted 8,829 shares, increasing direct ownership by 11% to 85,877 units (SEC Form 4)
- Director Kosaraju Sridhar was granted 8,829 shares, increasing direct ownership by 16% to 65,278 units (SEC Form 4)
- 10x Genomics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Executive Officer Saxonov Serge sold $709,057 worth of shares (28,893 units at $24.54) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,138,380 units (SEC Form 4) to satisfy withholding tax
- Officer Hindson Benjamin J. sold $283,399 worth of shares (11,595 units at $24.44), decreasing direct ownership by 2% to 502,000 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Taich Adam sold $369,018 worth of shares (15,098 units at $24.44), decreasing direct ownership by 4% to 379,898 units (SEC Form 4) to cover taxes
Latest WAT
- Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
- Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
- Wolfe Research resumed coverage on Waters with a new price target
- Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
- Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
- SEC Form SD filed by Waters Corporation
- SEC Form 8-K filed by Waters Corporation
- Waters Corporation to Present at the Jefferies Global Healthcare Conference
- SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 3% to 7,623 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Waters Corporation